Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Selected Financial Data since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Bristol-Myers Squibb Co., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings (loss) attributable to BMS1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 14, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Bristol-Myers Squibb Co. Annual Report.
The price-to-earnings (P/E) ratio exhibited considerable fluctuation between 2006 and 2024, with periods of both expansion and contraction. Initial values were relatively moderate, followed by significant volatility and a subsequent period of stabilization before another period of fluctuation. A notable outlier occurred in 2018, followed by a return to more moderate levels.
- Early Period (2006-2009)
- From 2006 to 2009, the P/E ratio demonstrated a marked increase from approximately 15 to a peak of 34.64, before declining sharply to 7.68. This initial increase coincided with a period of fluctuating earnings per share (EPS), while the subsequent decline likely reflects a combination of decreasing share price and increasing EPS. The lowest P/E ratio during the observed period occurred in 2009.
- Volatility and Stabilization (2010-2017)
- The period between 2010 and 2017 was characterized by substantial P/E ratio volatility. The ratio initially decreased to a low of 4.03 in 2010, then experienced fluctuations, peaking at 103.55 in 2018. This peak was driven by a significant decrease in EPS, while the share price remained relatively stable. Prior to this peak, the P/E ratio generally remained between 14 and 30, suggesting a period of relative stability, albeit with fluctuations.
- Recent Trends (2018-2024)
- Following the 2018 peak, the P/E ratio decreased to 16.81 in 2019, then increased to approximately 42 in 2020. A negative EPS value in 2020 resulted in a missing P/E ratio. From 2021 to 2023, the P/E ratio fluctuated between approximately 21 and 24, before decreasing to 12.27 in 2023. A missing P/E ratio is observed for 2024, coinciding with a negative EPS value.
Overall, the P/E ratio’s movements appear strongly correlated with changes in EPS, particularly in years with substantial earnings fluctuations. The high P/E ratio in 2018 suggests investors anticipated future earnings growth that did not materialize, or were willing to pay a premium for the stock despite low earnings. The negative EPS values in 2020 and 2024 resulted in undefined P/E ratios, indicating periods of unprofitability.
Comparison to Competitors
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | ||||||||||||
| Feb 12, 2025 | ||||||||||||
| Feb 13, 2024 | ||||||||||||
| Feb 14, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 10, 2021 | ||||||||||||
| Feb 24, 2020 | ||||||||||||
| Feb 25, 2019 | ||||||||||||
| Feb 13, 2018 | ||||||||||||
| Feb 21, 2017 | ||||||||||||
| Feb 12, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 14, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 17, 2012 | ||||||||||||
| Feb 18, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 20, 2009 | ||||||||||||
| Feb 22, 2008 | ||||||||||||
| Feb 26, 2007 | ||||||||||||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 11, 2026 | ||
| Feb 12, 2025 | ||
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 9, 2022 | ||
| Feb 10, 2021 | ||
| Feb 24, 2020 | ||
| Feb 25, 2019 | ||
| Feb 13, 2018 | ||
| Feb 21, 2017 | ||
| Feb 12, 2016 | ||
| Feb 13, 2015 | ||
| Feb 14, 2014 | ||
| Feb 15, 2013 | ||
| Feb 17, 2012 | ||
| Feb 18, 2011 | ||
| Feb 19, 2010 | ||
| Feb 20, 2009 | ||
| Feb 22, 2008 | ||
| Feb 26, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., P/E, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Feb 11, 2026 | ||
| Feb 12, 2025 | ||
| Feb 13, 2024 | ||
| Feb 14, 2023 | ||
| Feb 9, 2022 | ||
| Feb 10, 2021 | ||
| Feb 24, 2020 | ||
| Feb 25, 2019 | ||
| Feb 13, 2018 | ||
| Feb 21, 2017 | ||
| Feb 12, 2016 | ||
| Feb 13, 2015 | ||
| Feb 14, 2014 | ||
| Feb 15, 2013 | ||
| Feb 17, 2012 | ||
| Feb 18, 2011 | ||
| Feb 19, 2010 | ||
| Feb 20, 2009 | ||
| Feb 22, 2008 | ||
| Feb 26, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).